Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A.
J Clin Oncol. 2017 Aug 10;35(23):2624-2630. doi: 10.1200/JCO.2016.71.4394. Epub 2017 May 9.

Abstract

Purpose
Molecular diagnostic testing has become an integral part of the evaluation of patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next-generation sequencing (NGS), often identifies mutations with unclear clinical or prognostic implications. One such example is BRAF mutations that occur outside of codon 600 (non-V600BRAF mutations).

Methods
We conducted this multicenter, retrospective cohort study to characterize the clinical, pathologic, and survival implications of non-V600BRAF mutations in metastatic CRC. We pooled patients in whom non-V600BRAF mutations were identified from NGS databases at three large molecular genetics reference laboratories.

Results
A total of 9,643 patients with metastatic CRC underwent NGS testing. We identified 208 patients with non-V600BRAF mutations, which occurred in 2.2% of all patients tested and accounted for 22% of all BRAF mutations identified. Cancers with non-V600BRAF mutations, compared with cancers with V600E BRAF (V600EBRAF) mutations, were found in patients who were significantly younger (58 v 68 years, respectively), fewer female patients (46% v 65%, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sided primary tumors (36% v 81%, respectively).
Median overall survival was significantly longer in patients with non-V600BRAF-mutant metastatic CRC compared with those with both V600EBRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months, respectively; P , .001). In multivariable analysis, non-V600BRAF mutation was independently associated with improved overall survival (hazard ratio, 0.18; P , .001).

Conclusion
Non-V600BRAF mutations occur in approximately 2.2% of patients with metastatic CRC and define
a clinically distinct subtype of CRC with an excellent prognosis.

0 Comments
Submit a Comment

Your email address will not be published. Required fields are marked *

Share This
×